Belluscura (FRA:9VQ) Change In Receivables : €-1.38 Mil (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Belluscura Change In Receivables?

Belluscura's change in receivables for the quarter that ended in Jun. 2023 was €0.04 Mil. It means Belluscura's Accounts Receivable declined by €0.04 Mil from Dec. 2022 to Jun. 2023 .

Belluscura's change in receivables for the fiscal year that ended in Dec. 2022 was €-3.31 Mil. It means Belluscura's Accounts Receivable increased by €3.31 Mil from Dec. 2021 to Dec. 2022 .

Belluscura's Accounts Receivable for the quarter that ended in Jun. 2023 was €3.65 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Belluscura's Days Sales Outstanding for the six months ended in Jun. 2023 was 1,972.40.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Belluscura's liquidation value for the six months ended in Jun. 2023 was €8.51 Mil.

Belluscura Change In Receivables Historical Data

The historical data trend for Belluscura's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Belluscura Change In Receivables Chart

Belluscura Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

0.26

-0.57

0.07

-1.66

-3.31

Belluscura Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial				0.37	-2.06	-1.88	-1.43	0.04

Belluscura Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-1.38 Mil.

Belluscura (FRA:9VQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Belluscura's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.653	/	0.338	*	91
=	1,972.40

2. In Ben Graham's calculation of liquidation value, Belluscura's accounts receivable are only considered to be worth 75% of book value:

Belluscura's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.53	-	1.826	+	0.75 * 3.653	+	0.5 * 8.126
=	8.51

Belluscura Change In Receivables Related Terms

Thank you for viewing the detailed overview of Belluscura's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Belluscura (FRA:9VQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Belluscura PLC (FRA:9VQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BELL:UK

Address

15 Fetter Lane, Holborn, London, GBR, EC4A 1BW

Website

https://www.belluscura.com

Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.

Belluscura (FRA:9VQ) Headlines

No Headlines